ASCO 2023

The SWOG S1826 study

6 June 2023

Dr. Claudio Cerchione, representing the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori in Meldola, provided commentary on the latest SWOG S1826 study presented by Dr. Alex Francisco Herrera of the City of Hope National Medical Center. This study is focused on a randomized comparison between nivolumab-AVD and brentuximab vedotin-AVD for advanced stage (AS) classic Hodgkin lymphoma (HL). 

See full coverage from ASCO

With the educational support of:

Tags:

Share Article